Sutro Biopharma, Inc. (STRO) earnings
STRO earnings moved a median of -9.30% by the close. Quarterly and annual STRO reports and results, each read against the price at its own news timestamp. Back to the STRO overview →
21 measured STRO earnings events.
Where these STRO earnings landedvs 21 measured STRO earnings reactions
| Middle 50% of STRO earnings reactions | -11.13% to +1.55% |
|---|---|
| Median reaction (to close) | -9.30% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 STRO earnings events with a measured close landed between -11.13% and +1.55%; 38% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q SUTRO BIOPHARMA, INC. For: Jun 30 | SEC filing · Form 10-Q | -3.18% | -9.71% | |
| Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study | Press release | -3.18% | -9.71% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Mar 31 | SEC filing · Form 10-Q | -9.92% | -11.13% | |
| Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights | Press release | -9.92% | -11.13% | |
| Form 10-K SUTRO BIOPHARMA, INC. For: Dec 31 | SEC filing · Form 10-K | -6.29% | +1.55% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Sep 30 | SEC filing · Form 10-Q | -4.04% | -9.30% | |
| Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | -4.04% | -9.30% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Jun 30 | SEC filing · Form 10-Q | +1.13% | -0.22% | |
| Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | +1.13% | -0.22% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Mar 31 | SEC filing · Form 10-Q | -0.35% | -12.85% | |
| Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights | Press release | -0.35% | -12.85% | |
| Form 10-K SUTRO BIOPHARMA, INC. For: Dec 31 | SEC filing · Form 10-K | -14.82% | -18.99% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Sep 30 | SEC filing · Form 10-Q | +0.51% | -11.31% | |
| Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights | Press release | +0.51% | -11.31% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Jun 30 | SEC filing · Form 10-Q | +0.56% | +1.13% | |
| Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones | Press release | +0.56% | +1.13% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Mar 31 | SEC filing · Form 10-Q | +3.79% | +2.84% | |
| Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones | Press release | +3.79% | +2.84% | |
| Form 10-K SUTRO BIOPHARMA, INC. For: Dec 31 | SEC filing · Form 10-K | -1.33% | +11.47% | |
| Form 10-Q SUTRO BIOPHARMA, INC. For: Sep 30 | SEC filing · Form 10-Q | +8.25% | +15.05% | |
| Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones | Press release | +8.25% | +15.05% |
Keep exploring
More STRO: analyst actions → · SEC filings → · STRO overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| InspireMD Inc. (NSPR) | 271 | 0.00% | 39% |
| Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) | 271 | -0.69% | 33% |
| PRESBIA PLC ORDINARY SHARES (LENS) | 270 | 0.00% | 42% |
| Achieve Life Sciences, Inc. - Common Shares (ACHV) | 269 | -0.54% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.